全文获取类型
收费全文 | 28541篇 |
免费 | 2148篇 |
国内免费 | 134篇 |
专业分类
耳鼻咽喉 | 177篇 |
儿科学 | 770篇 |
妇产科学 | 730篇 |
基础医学 | 3640篇 |
口腔科学 | 747篇 |
临床医学 | 2807篇 |
内科学 | 5893篇 |
皮肤病学 | 438篇 |
神经病学 | 3084篇 |
特种医学 | 1073篇 |
外科学 | 3867篇 |
综合类 | 434篇 |
一般理论 | 22篇 |
预防医学 | 2604篇 |
眼科学 | 430篇 |
药学 | 1724篇 |
中国医学 | 37篇 |
肿瘤学 | 2346篇 |
出版年
2023年 | 295篇 |
2022年 | 440篇 |
2021年 | 869篇 |
2020年 | 595篇 |
2019年 | 803篇 |
2018年 | 913篇 |
2017年 | 684篇 |
2016年 | 771篇 |
2015年 | 784篇 |
2014年 | 1155篇 |
2013年 | 1452篇 |
2012年 | 2281篇 |
2011年 | 2273篇 |
2010年 | 1189篇 |
2009年 | 994篇 |
2008年 | 1770篇 |
2007年 | 1723篇 |
2006年 | 1523篇 |
2005年 | 1523篇 |
2004年 | 1384篇 |
2003年 | 1180篇 |
2002年 | 1101篇 |
2001年 | 398篇 |
2000年 | 378篇 |
1999年 | 363篇 |
1998年 | 244篇 |
1997年 | 167篇 |
1996年 | 168篇 |
1995年 | 153篇 |
1994年 | 138篇 |
1993年 | 127篇 |
1992年 | 278篇 |
1991年 | 230篇 |
1990年 | 193篇 |
1989年 | 187篇 |
1988年 | 159篇 |
1987年 | 177篇 |
1986年 | 159篇 |
1985年 | 167篇 |
1984年 | 105篇 |
1983年 | 124篇 |
1982年 | 68篇 |
1981年 | 72篇 |
1979年 | 81篇 |
1978年 | 80篇 |
1974年 | 72篇 |
1973年 | 62篇 |
1972年 | 74篇 |
1971年 | 80篇 |
1968年 | 63篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Jasmine Poonian Nicola Walsham Thomas Kilner Elizabeth Bradbury Kristen Brooks Emma West 《Emergency medicine Australasia : EMA》2020,32(4):700-702
Emergency Medicine staff in Australia and New Zealand are at the forefront of the healthcare response to COVID‐19. This article describes a well‐being plan for ED staff that has been devised to mitigate against the negative psychological impact of the COVID‐19 pandemic. 相似文献
3.
4.
5.
6.
7.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献8.
Nicola Flaum Emma J. Crosbie Richard J. Edmondson Miriam J. Smith Dafydd G. Evans 《Clinical genetics》2020,97(1):54-63
Ovarian cancer is the fourth most common cause of cancer-related death in women in the developed world, and one of the most heritable cancers. One of the most significant risk factors for epithelial ovarian cancer (EOC) is a family history of breast and/or ovarian cancer. Combined risk factors can be used in models to stratify risk of EOC, and aid in decisions regarding risk-reduction strategies. Germline pathogenic variants in EOC susceptibility genes including those involved in homologous recombination and mismatch repair pathways are present in approximately 22% to 25% of EOC. These genes are associated with an estimated lifetime risk of EOC of 13% to 60% for BRCA1 variants and 10% to 25% for BRCA2 variants, with lower risks associated with remaining genes. Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) thought to explain an additional 6.4% of the familial risk of ovarian cancer, with 34 susceptibility loci identified to date. However, an unknown proportion of the genetic component of EOC risk remains unexplained. This review comprises an overview of individual genes and SNPs suspected to contribute to risk of EOC, and discusses use of a polygenic risk score to predict individual cancer risk more accurately. 相似文献
9.
Oga Emmanuel. A. Peters Erica. N. Mark Katrina Trocin Kathleen Coleman-Cowger Victoria. H. 《Maternal and child health journal》2019,23(2):250-257
Maternal and Child Health Journal - Background Prenatal substance use screening is recommended. The 4 P’s Plus screener includes questions on perceived problematic substance use in parents... 相似文献